期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吡格列酮治疗2型糖尿病的疗效观察 被引量：2

暂未订购
导出
摘要 目的:观察吡格列酮对2型糖尿病的降糖、调脂疗效。方法:将48例2型糖尿病患者随机分为治疗组和对照组,治疗组加用吡格列酮30 mg,每日1次早餐前30 min口服,对照组加用安慰剂,疗程均12周。观察两组治疗前后糖、脂代谢相关指标的变化。结果:治疗组空腹及餐后2 h血糖、空腹胰岛素、空腹C肽、糖化血红蛋白、血清总胆固醇较服药前有明显降低,与对照组比较有显著性差异(P<0.05)。结论:吡格列酮可有效降低2型糖尿病患者的血糖、血脂,改善胰岛素抵抗。
作者 左春林 王长江 杨明功 何勇 孙海燕
机构地区 安徽医科大学第一附属医院内分泌科
出处 《广东药学院学报》 CAS 2002年第4期331-332,共2页 Academic Journal of Guangdong College of Pharmacy
关键词 疗效观察 吡格列酮 2型糖尿病 药物疗法 治疗
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献5

  • 1Lehmann JM, Moore LB, Smith - Oliver TA et al. An antidiabet ie thiazolidinedione is a high affinity ligand for peroxisome pro liferator - activated receptor γ ( PPAR γ) [ J ]. J Biol Chem, 1995,270:129.
  • 2Schoonjans K, Martin G, Staels B, et al. Peroxisome proliferator -activated receptors,orphans with ligands and functions [ J ]. Curr Opin Lipidol, 1997,8:159.
  • 3Hayakawa T,Shiraki T, Morimoto T, et al. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats [ J ]. Biochem Biophys Res Commun, 1996,223: 439.
  • 4Digyb JE, Montague CT, Stewter CP, et al. Thiazolidinedione ex posure increases the expression of uncoupling protein 1 in cultured human preadipocytes [ J ]. Diabetes, 1998,47:138.
  • 5王长江,刘树琴,章秋,杨明功,叶山东,王德全,罗佐杰,阎胜利.盐酸吡格列酮治疗2型糖尿病的疗效及安全性[J].中国临床药理学杂志,2002,18(3):167-170. 被引量：13

二级参考文献11

  • 1[1]Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study(UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin endocrinol Diabetes, 1998; 106:369～372.
  • 2[2]Haffner SM. Epdemiology of insulin resistance and its relation to coronary artery disease. American J Cardiology, 1999; 84:11 ～ 14.
  • 3[3]Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferactor-activated receptor γ. J Biol Chem, 1995; 270:129～153.
  • 4[4]Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes,1997; 46:1393～ 1399.
  • 5[5]Kemnitz JW, Elson DF, Roecker EB, et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels,and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes, 1994; 43:204～211.
  • 6[6]Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther, 2001; 23:1792～1823.
  • 7[7]Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis, 2001; 12:413～423.
  • 8[8]Hanefeld M, Belcher G. Safety profile of pioglitazone. Iht J Clin Pract, 2001, 121:27～31.
  • 9[9]Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf, 2001; 24 873～888.
  • 10[10]Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.Clin Ther, 2000; 22:1395～1409.

共引文献12

同被引文献4

二级引证文献5

广东药学院学报
2002年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部